- Home
- BBNX vs LYEL Comparison
BBNX vs LYEL Comparison
Compare BBNX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBNX | LYEL |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.7M | 490.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBNX | LYEL |
|---|---|---|
| Price | $11.57 | $23.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $26.73 | $25.00 |
| AVG Volume (30 Days) | ★ 1.2M | 95.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,000.00 |
| Revenue This Year | $35.03 | N/A |
| Revenue Next Year | $33.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.89 | $0.39 |
| 52 Week High | $32.71 | $45.00 |
Technical Indicators
Market Signals| Indicator | BBNX | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 25.10 | 48.77 |
| Support Level | N/A | $21.27 |
| Resistance Level | $15.53 | $27.30 |
| Average True Range (ATR) | 0.95 | 2.19 |
| MACD | 0.17 | 0.14 |
| Stochastic Oscillator | 2.05 | 50.22 |
Price Performance
Historical ComparisonAbout BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.